Format

Send to

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2014 Aug;58(8):4920-2. doi: 10.1128/AAC.02703-13. Epub 2014 May 27.

In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal.

Author information

1
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan iwata_atsushi@kaken.co.jp.
2
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan.
3
Dow Pharmaceutical Sciences, Valeant Pharmaceuticals N.A. LLC, Petaluma, California, USA.

Abstract

Efinaconazole is a novel triazole antifungal drug for the topical treatment of onychomycosis, a nail infection caused mainly by dermatophytes. We assessed the potential of efinaconazole to induce resistance in dermatophytes by continuous exposure of Trichophyton rubrum strains to efinaconazole in vitro (12 passages) and in a guinea pig onychomycosis model (8 weeks). There was no evidence of efinaconazole resistance development in the tested strains under the experimental conditions used.

PMID:
24867968
PMCID:
PMC4136074
DOI:
10.1128/AAC.02703-13
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center